Key clinical point: Treatment with DMT for more than 10 years reduces the risk of confirmed disability progression in MS.
Major finding: Continuous treatment with DMT reduced the risk of 24-month confirmed disability progression by 35%.
Study details: A retrospective analysis of data for 15,602 patients with relapsing-remitting MS.
Disclosures: Two of the researchers are employees of Biogen International, which supported the research. Several investigators received compensation or funding from various pharmaceutical companies.